Statement of preliminary issues for Pfizer’s application to acquire Hospira
The Commerce Commission has published a statement of preliminary issues relating to an application from Pfizer to
acquire all of the remaining shares in Hospira.
Pfizer and Hospira are both global companies that manufacture and supply pharmaceutical products.
The statement of preliminary issues outlines the key competition issues that the Commission currently considers will be
important in deciding whether or not to grant clearance.
The Commission invites submissions from parties who consider that they have information relevant to the Commission’s
consideration of this matter.
Submissions can be sent by email to registrar@comcom.govt.nz with the reference Pfizer / Hospira in the subject line, or
by mail to PO Box 2351, Wellington 6140. Any submissions should be received by close of business 29 May 2015.
The statement of preliminary issues and a public version of the application can be found on the Commission’s Clearances
Register which is accessible through our website.
ends